Sorry, you need to enable JavaScript to visit this website.
Skip to main content

Search

Jennifer Taubert

Jennifer Taubert

JENNIFER TAUBERT

Executive Vice President
Worldwide Chairman, Pharmaceuticals
Johnson & Johnson

Jennifer Taubert is Executive Vice President, Worldwide Chairman, Pharmaceuticals at Johnson & Johnson, the world’s largest health care company. She is a member of the Corporation’s Executive Committee and leads the Pharmaceuticals Group Operating Committee. 

Jennifer has been a leader in shaping Janssen’s global strategy of transformational medical innovation, successfully bringing to market critical new medicines that significantly improve the lives of patients living with cancer, immune-related diseases, heart disease and diabetes, infectious diseases including HIV, pulmonary hypertension and serious mental illness. Under her leadership Janssen has become the world’s third-largest innovative pharmaceutical business and remains a significant contributor to Johnson & Johnson’s growth. Jennifer is also recognized as a champion of diversity and inclusion, which she sees as critical to insight, innovation and business success.

Prior to being named to her current role, as Company Group Chairman, The Americas, Jennifer led businesses that were a major catalyst of Johnson & Johnson’s growth, doubling in size and consistently outpacing the industry to become the number one pharmaceutical company in the U.S. and Canada. Jennifer joined Johnson & Johnson in 2005 to lead global commercial strategy for Internal Medicine in the Pharmaceuticals Group. Later, as President, Internal Medicine, she built a powerhouse new franchise in cardiovascular and metabolic disease. Before joining Johnson & Johnson, Jennifer spent 18 years in positions of increasing scope and responsibility at Merck and Allergan. Jennifer was named to Fortune magazine’s “Most Powerful Women” list the past four years, and received the National Association for Female Executives’ 2017 “Woman of Achievement” award.

Jennifer represents Johnson & Johnson on the Board of Directors of the Biotechnology Innovation Organization (BIO), the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations, and on the Executive Committee of the International Section of the Pharmaceutical Research and Manufacturers of America (PhRMA). She also serves on the National Academy of Medicine’s Leadership Consortium: Collaboration for a Value & Science-Driven Learning Health System, and on the Advisory Board of the Leonard D. Schaeffer Center for Health Policy and Economics at the University of Southern California.

Jennifer received a bachelor’s degree in Pharmacology from the University of California, Santa Barbara and a Master of Business Administration from the Anderson Graduate School of Management, University of California, Los Angeles.